June 14, 2007 (San Diego) — Final examination results of the yearlong RIO-Lipids endeavour of the volume selective CB1 sense organ endocannabinoid medication rimonabant (Acomplia) suggest that the single-agent motion to treating multiple eudaimonia issues associated with diabetes may soon become the ideal. Rimonabant, the number 1 in the new drug division of CB1 blockers, was found to improve hemoglobin A1c (HbA1c) levels, reduce lipid levels and rip pressing, and reduce oppressiveness and part size, researchers reported here at the American Diabetes Association's 65th Plant life Scientific Sessions.
In patients who took the 20-mg dose of rimonabant, HbA1c dropped by 0.7% from service line levels of 7.3%, and sports equipment simplification and area delimitation were reduced 11.7 lb and 2 in, respectively, compared with those taking medicament. High-density lipoprotein (HDL) cholesterol and triglyceride levels were also significantly improved.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment